Matches in SemOpenAlex for { <https://semopenalex.org/work/W4677652> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4677652 endingPage "31" @default.
- W4677652 startingPage "21" @default.
- W4677652 abstract "Anemia is a frequent clinical feature with adverse prognostic effects in patients with chronic lymphocytic leukemia (CLL). It may complicate CLL at any time during the course of the disease. Different factors concur to the occurrence of anemia in CLL, as in other lymphoproliferative diseases: leukemic bone marrow infiltration, the myelosuppressive effect of chemotherapy and inhibiting cytokines, autoimmune phenomena, hypersplenism, a poor nutritional status that leads to folic acid, vitamin B12 and iron deficiency. In addition, a defective endogenous erythropoietin (EPO) production has also been described in patients with lymphoproliferative diseases. The severity of anemia, which may be worsened by an impaired cardiopulmonary function, may profoundly compromise the patients' quality of life and, indirectly, the outcome of cancer bearing patients. Several Authors have reported the clinical activity of recombinant human (rHu)EPO in anemic patients with lymphoproliferative diseases, including CLL. Low serum EPO levels at baseline and EPO levels inappropriately low for the degree of anemia help to identify patients who are likely to respond to EPO. A clear dose-dependent response to EPO has been reported by different Authors and it has been suggested that 5,000 IU should be considered as an appropriate initial dose for the majority of patients. rHuEPO represents a potentially effective and safe therapy for the management of anemia associated with lymphoproliferative diseases. The reduction of red blood cell transfusion requirement, the improvement of quality of life through the remission of fatigue-related anemia are two important results that should be considered in the management of patients with CLL. In prospect, the availability of new rHuEPO molecules with a more prolonged half-life may open new therapeutic avenues." @default.
- W4677652 created "2016-06-24" @default.
- W4677652 creator A5009431453 @default.
- W4677652 creator A5021492292 @default.
- W4677652 creator A5042796311 @default.
- W4677652 date "2002-01-01" @default.
- W4677652 modified "2023-10-14" @default.
- W4677652 title "Erythropoietin and chronic lymphocytic leukemia." @default.
- W4677652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12735212" @default.
- W4677652 hasPublicationYear "2002" @default.
- W4677652 type Work @default.
- W4677652 sameAs 4677652 @default.
- W4677652 citedByCount "4" @default.
- W4677652 countsByYear W46776522018 @default.
- W4677652 crossrefType "journal-article" @default.
- W4677652 hasAuthorship W4677652A5009431453 @default.
- W4677652 hasAuthorship W4677652A5021492292 @default.
- W4677652 hasAuthorship W4677652A5042796311 @default.
- W4677652 hasConcept C126322002 @default.
- W4677652 hasConcept C203014093 @default.
- W4677652 hasConcept C2776995267 @default.
- W4677652 hasConcept C2777938653 @default.
- W4677652 hasConcept C2778248108 @default.
- W4677652 hasConcept C2778461978 @default.
- W4677652 hasConcept C2778534260 @default.
- W4677652 hasConcept C2778740236 @default.
- W4677652 hasConcept C2779338263 @default.
- W4677652 hasConcept C2779750884 @default.
- W4677652 hasConcept C2780007613 @default.
- W4677652 hasConcept C71924100 @default.
- W4677652 hasConcept C90924648 @default.
- W4677652 hasConceptScore W4677652C126322002 @default.
- W4677652 hasConceptScore W4677652C203014093 @default.
- W4677652 hasConceptScore W4677652C2776995267 @default.
- W4677652 hasConceptScore W4677652C2777938653 @default.
- W4677652 hasConceptScore W4677652C2778248108 @default.
- W4677652 hasConceptScore W4677652C2778461978 @default.
- W4677652 hasConceptScore W4677652C2778534260 @default.
- W4677652 hasConceptScore W4677652C2778740236 @default.
- W4677652 hasConceptScore W4677652C2779338263 @default.
- W4677652 hasConceptScore W4677652C2779750884 @default.
- W4677652 hasConceptScore W4677652C2780007613 @default.
- W4677652 hasConceptScore W4677652C71924100 @default.
- W4677652 hasConceptScore W4677652C90924648 @default.
- W4677652 hasLocation W46776521 @default.
- W4677652 hasOpenAccess W4677652 @default.
- W4677652 hasPrimaryLocation W46776521 @default.
- W4677652 hasRelatedWork W2020552840 @default.
- W4677652 hasRelatedWork W2064126141 @default.
- W4677652 hasRelatedWork W2092409694 @default.
- W4677652 hasRelatedWork W2159812471 @default.
- W4677652 hasRelatedWork W2336677378 @default.
- W4677652 hasRelatedWork W2340078765 @default.
- W4677652 hasRelatedWork W2408887586 @default.
- W4677652 hasRelatedWork W2413463162 @default.
- W4677652 hasRelatedWork W3035549666 @default.
- W4677652 hasRelatedWork W4677652 @default.
- W4677652 hasVolume "Suppl 1" @default.
- W4677652 isParatext "false" @default.
- W4677652 isRetracted "false" @default.
- W4677652 magId "4677652" @default.
- W4677652 workType "article" @default.